Seaport Therapeutics, Inc. (SPTX)
| Market Cap | 927.99M |
| Revenue (ttm) | n/a |
| Net Income | -74.88M |
| EPS | -10.04 |
| Shares Out | 53.03M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 214,579 |
| Open | 17.19 |
| Previous Close | 17.19 |
| Day's Range | 16.53 - 17.69 |
| 52-Week Range | 14.85 - 23.00 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Jun 5, 2026 |
About SPTX
Seaport Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company advancing the development of novel neuropsychiatric medicines. The company develops therapeutic candidates for conditions such as depression and anxiety disorders using its proprietary Glyph technology platform. The Glyph platform is designed to enable oral bioavailability, bypass first-pass metabolism, and reduce liver enzyme elevations or hepatotoxicity and other side effects. All therapeutic candidates in development are based on this platform, with research an... [Read more]
Financial Performance
Financial StatementsNews
Opening Day: Pershing Square listings open soft in market debut
Pershing Square USA and Pershing Square Inc. began trading on April 29, marking the public debut of Bill Ackman’s two vehicle structure. LATEST IPOS AND DIRECT LISTINGS: Seaport Therapeutics (SPTX)…
Seaport Therapeutics opens at $21, IPO priced at $18 per share
Seaport Therapeutics (SPTX) priced 14.2M shares at $18.00. The deal size was increased to 14.2M shares of common stock from 11.8M shares and priced at the high-end of the $16.00-$18.00…
Seaport Therapeutics 14.2M share IPO priced at $18.00
The deal size was increased to 14.2M shares of common stock from 11.8M shares of common stock and priced at the high-end of the $16.00-$18.00 range. Goldman Sachs, JPMorgan, Leerink,…
Seaport Therapeutics raises about $255 million in upsized IPO
Drug developer Seaport Therapeutics said on Thursday it had raised about $255 million in its upsized initial public offering in the United States.
Seaport Therapeutics Announces Pricing of Upsized Initial Public Offering
BOSTON--(BUSINESS WIRE)--Seaport Therapeutics Announces Pricing of Upsized Initial Public Offering.
Seaport Therapeutics prices 14.6M share IPO a $18, top of range, Bloomberg says
19:34 EDT Seaport Therapeutics (SPTX) prices 14.6M share IPO a $18, top of range, Bloomberg says
Drug developer Seaport Therapeutics targets $912 million valuation in US IPO
Drug developer Seaport Therapeutics said on Monday it was aiming for a valuation of $912 million in its initial public offering in the United States.
Seaport Therapeutics IPO Registration Document (S-1)
Seaport Therapeutics has filed to go public with an IPO on the NASDAQ
Seaport Therapeutics IPO Registration Document (S-1)
Seaport Therapeutics has filed to go public with an IPO on the NASDAQ